FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound

CNBC
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Read the full story
This is a short summary. The complete article is published by CNBC.
Continue at CNBC

Headline and summary aggregated from public news feeds. For information only — not financial advice.